Haddock Jason 4
4 · ARRAY BIOPHARMA INC · Filed Feb 8, 2019
Insider Transaction Report
Form 4
Transactions
- Sale
Common Stock
2019-02-07$22.05/sh−85,000$1,874,301→ 30,059 total - Sale
Common Stock
2019-02-06$20.00/sh−11,712$234,240→ 30,059 total - Exercise/Conversion
Stock Option (Right to Buy)
2019-02-07−85,000→ 404,450 totalExercise: $3.77Exp: 2026-07-28→ Common Stock (85,000 underlying) - Exercise/Conversion
Common Stock
2019-02-07$3.77/sh+85,000$320,450→ 115,059 total
Footnotes (3)
- [F1]These trades were made pursuant to a Rule 10b5-1 trading plan.
- [F2]The price reported for these shares is the weighted average sale price of transactions made at prices from $22.00 to $22.12. Details of actual prices for shares sold are available from the Issuer upon request.
- [F3]The options vest in four equal annual installments beginning on July 28, 2017.